145 related articles for article (PubMed ID: 20861140)
1. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
[TBL] [Abstract][Full Text] [Related]
3. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
[TBL] [Abstract][Full Text] [Related]
4. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
5. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2005 May; 55(5):727-34. PubMed ID: 15761070
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
7. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
[TBL] [Abstract][Full Text] [Related]
8. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model.
Sivak O; Gershkovich P; Lin M; Wasan EK; Zhao J; Owen D; Clement JG; Wasan KM
Lipids Health Dis; 2011 Aug; 10():135. PubMed ID: 21824435
[TBL] [Abstract][Full Text] [Related]
9. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
10. Study of the toxicity of a new lipid complex formulation of amphotericin B.
Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis.
Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Bartlett K; Wasan KM
Int J Pharm; 2012 Oct; 436(1-2):318-23. PubMed ID: 22772485
[TBL] [Abstract][Full Text] [Related]
12. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
Zhang Z; Diener RM; Lipman JM
Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
[TBL] [Abstract][Full Text] [Related]
13. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
[TBL] [Abstract][Full Text] [Related]
14. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
[TBL] [Abstract][Full Text] [Related]
15. High purity amphotericin B.
Cleary JD; Chapman SW; Swiatlo E; Kramer R
J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B formulations and drug targeting.
Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
[TBL] [Abstract][Full Text] [Related]
17. Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model.
Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM
Eur J Pharm Sci; 2012 Aug; 46(5):323-8. PubMed ID: 22369857
[TBL] [Abstract][Full Text] [Related]
18. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
Thornton SJ; Wasan KM
Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
[TBL] [Abstract][Full Text] [Related]
19. Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits.
Clemons KV; Sobel RA; Williams PL; Stevens DA
Antimicrob Agents Chemother; 2001 Feb; 45(2):612-5. PubMed ID: 11158765
[TBL] [Abstract][Full Text] [Related]
20. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B.
Jain S; Valvi PU; Swarnakar NK; Thanki K
Mol Pharm; 2012 Sep; 9(9):2542-53. PubMed ID: 22845020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
